{"preliminary_commentary":{"by_channel":{"x_thread":145,"youtube":32,"podcast":9,"bluesky_thread":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02620280\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-30T23:16:52.283Z","note":"Automated from the 40 newest of 190 indexed sources (Jun 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- What explains differences in atezolizumab outcomes across early TNBC studies\n- Whether anthracyclines are needed alongside immunotherapy\n- How confidently to interpret the immunotherapy findings\n\nAlso discussed: transcriptomic response biomarkers, CD204+ macrophages.","kind":"questions"},"drugs_tested":[["atezolizumab"]],"indication":"early high-risk and locally advanced triple-negative breast cancer","name":"NeoTRIP","nct_id":"NCT02620280","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neotrip-nct02620280. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NeoTRIPaPDL1","arms":[{"description":"Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy","label":"Carbo-abrax, surgery, anthra","type":"ACTIVE_COMPARATOR"},{"description":"Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy","label":"Carbo-abrax-MPDL3280A, surgery, anthra","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-01-07","type":"ACTUAL"},"conditions":["Invasive Ductal Breast Carcinoma"],"enrollment":{"count":278,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Carboplatin","otherNames":["Carboplatin Teva"],"type":"DRUG"},{"name":"Abraxane","otherNames":["nab-paclitaxel"],"type":"DRUG"},{"name":"MPDL3280A","otherNames":["Atezolizumab"],"type":"DRUG"},{"name":"Surgery","otherNames":[],"type":"PROCEDURE"},{"name":"Anthra","otherNames":[],"type":"DRUG"}],"last_update":"2024-03-06","lead_sponsor":"Fondazione Michelangelo","official_title":"Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event Free Survival (EFS)","timeFrame":"5 years after the randomization of the last patient"}],"references":[{"citation":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17.","pmid":"35182721","type":"DERIVED"},{"citation":"Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.","pmid":"32450725","type":"DERIVED"}],"start_date":{"date":"2016-04"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","url":"https://clinicaltrials.gov/study/NCT02620280"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neotrip-nct02620280"}